InterMune Launches Esbriet in Germany At Better-Than-Expected Price
This article was originally published in The Pink Sheet Daily
German pricing for InterMune's IPF drug Esbriet surprises on the upside, but will it last?
You may also be interested in...
Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.
Intermune’s Esbriet Flops In Front Of IQWiG
Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology